Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Pharmacology

Background:

• Current guidelines recommend inhaled corticosteroids for persistent pediatric asthma.
• Traditional inhaler devices pose challenges for young children's correct usage.
• Limited inhaled corticosteroid options were approved for children under 4 years.

Purpose of the Study:

• To introduce budesonide inhalation suspension as a novel treatment for infants and young children with persistent asthma.
• To highlight its suitability for nebulizer administration, addressing previous device limitations.
• To present US-based clinical trial data on its efficacy and tolerability.

Main Methods:

• Three placebo-controlled, multicenter trials were conducted in the United States.
• Budesonide inhalation suspension was administered via nebulizer.
• Dosing regimens included once- and twice-daily administration of 0.25-1 mg.

Main Results:

• Budesonide inhalation suspension demonstrated significant improvements in pulmonary function.
• Asthma symptoms were ameliorated in infants and young children with persistent asthma.
• The suspension was well-tolerated, with adverse event rates comparable to placebo and conventional therapies.

Conclusions:

• Budesonide inhalation suspension is an effective and safe inhaled corticosteroid for managing persistent asthma in young children.
• Its approval for infants as young as 12 months and nebulizer delivery addresses critical unmet needs.
• Clinical trials confirm its tolerability and efficacy, supporting its use in this population.